IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 800,500 shares, a drop of 78.7% from the February 13th total of 3,760,000 shares. Based on an average trading volume of 5,060,000 shares, the short-interest ratio is currently 0.2 days. Approximately 1.2% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of INAB. Jane Street Group LLC increased its position in IN8bio by 296.7% during the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock worth $30,000 after buying an additional 86,696 shares in the last quarter. Geode Capital Management LLC raised its stake in IN8bio by 56.5% in the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after purchasing an additional 185,919 shares during the last quarter. Sigma Planning Corp lifted its holdings in IN8bio by 22.3% in the 4th quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after purchasing an additional 190,100 shares in the last quarter. AIGH Capital Management LLC boosted its stake in shares of IN8bio by 269.7% during the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after purchasing an additional 4,517,227 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its holdings in shares of IN8bio by 1,064.5% during the fourth quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after buying an additional 4,628,482 shares in the last quarter. 92.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of IN8bio in a report on Wednesday, February 12th.

IN8bio Price Performance

Shares of IN8bio stock traded up $0.00 on Wednesday, hitting $0.25. The company’s stock had a trading volume of 675,576 shares, compared to its average volume of 6,769,527. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average price of $0.28 and a 200-day moving average price of $0.30. IN8bio has a 52-week low of $0.22 and a 52-week high of $1.74. The company has a market capitalization of $20.07 million, a P/E ratio of -0.33 and a beta of 0.03.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.